The news seems to have dried up as we head into the long weekend. We had “positive” jobs data that seems to be sparking a rally. While the data are good, it is also on the back of the expanded epidemic so it seems a little unsustainable as there have been repeated closings in the […]
The market seems to be a little indecisive at this point. We are getting some moves but nothing that seems sustained and only to be reversed to the other side. At this point, it seems the sector has retested the breakout levels and all else being equal should be setup for a continued move higher. […]
Sorry, I missed writing on Monday as I try to stay as consistent as possible on Monday as I think it sets up the week. My daughter went on a beech vacation with her friend and their family late last week. Long story short, she got home sick and led to being physically ill, so […]
The sector remains strong with a green day yesterday as well as a relative outperformance to the broader market. I guess COVID will not matter until it does but I remain worried that it is only a matter of time before case growth (and like deaths) become too high to ignore. This morning we seem […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.